Atrial Fibrillation: Diagnosis and Management

Written by Dr. Muhammad Salar Raza · Manually reviewed by Dr. Muhammad Salar Raza · Content updated

Clinical Pathway

Confirm atrial fibrillation with an ECG showing absent P waves and an irregularly irregular ventricular response. Assess hemodynamic stability first: hypotension, ischemic chest pain, pulmonary edema, or syncope mandate urgent synchronized electrical cardioversion. In stable patients, control the ventricular rate with a beta blocker or rate-limiting calcium channel blocker, and consider rhythm control for symptomatic or new-onset AF. Estimate stroke risk with CHA2DS2-VASc and start anticoagulation, preferably a direct oral anticoagulant, in patients at elevated risk. Investigate triggers and comorbidities: hypertension, thyrotoxicosis, valvular disease, alcohol, and electrolyte disturbance.

Clinical Reasoning

Two questions organize every AF decision: is the patient unstable, and what is the stroke risk? Instability overrides everything and leads straight to cardioversion regardless of AF duration. For stable patients, anticoagulation decisions are based on CHA2DS2-VASc rather than whether AF is paroxysmal or persistent; stroke risk is equivalent across patterns. Rate control is not inferior to rhythm control for most older patients, while younger symptomatic patients benefit from rhythm strategies. Warfarin remains indicated for mechanical valves and moderate to severe mitral stenosis, where DOACs are contraindicated.

Sample MCQ

A 74-year-old woman with hypertension and diabetes presents with palpitations. ECG shows atrial fibrillation at 110 beats per minute. She is hemodynamically stable. Her CHA2DS2-VASc score is 4. Which intervention most reduces her risk of stroke?

  • AApixaban
  • BAspirin monotherapy
  • CDigoxin
  • DNo therapy while she remains asymptomatic

Correct Answer: Apixaban

A CHA2DS2-VASc score of 4 indicates high stroke risk, and oral anticoagulation with a direct oral anticoagulant such as apixaban is the standard of care. Aspirin monotherapy is no longer recommended for stroke prevention in AF because it provides minimal protection with real bleeding risk. Digoxin only slows the ventricular rate; it has no effect on thromboembolism. Withholding therapy exposes her to a substantially elevated risk of cardioembolic stroke, and stroke risk is independent of symptoms, so asymptomatic status does not remove the indication for anticoagulation.

Guidelines and further reading

Related Clinical Topics

Acute Coronary Syndrome (ACS): Diagnosis and Emergency Management

Suspect ACS in any patient with prolonged ischemic chest pain, and obtain a 12-lead ECG within 10 minutes of arrival. Give chewable aspirin 162-325 mg and draw high-sensitivity troponin. ST-segment elevation (STEMI) requires immediate reperfusion: primary PCI within 90 minutes of first medical contact, or fibrinolysis within 30 minutes if timely PCI is unavailable. NSTEMI and unstable angina are managed with dual antiplatelet therapy, anticoagulation, high-intensity statin, and risk-stratified invasive evaluation. Treat pain with nitrates if no contraindication, control blood pressure and heart rate with a beta blocker once stable, and screen for complications such as arrhythmia and acute heart failure.

Stable Angina Pectoris: Clinical Evaluation

Stable angina is characterized by episodic chest discomfort that is predictably provoked by exertion or emotional stress and relieved by rest or nitroglycerin. The initial evaluation involves a thorough history and physical examination, followed by a resting ECG. If the patient can exercise and has a normal resting ECG, an exercise stress test (treadmill ECG) is the preferred initial non-invasive functional test for diagnosing ischemic heart disease. Patients with abnormal resting ECGs or inability to exercise require imaging-based stress testing (e.g., stress echocardiography or nuclear perfusion imaging).

Heart Failure with Reduced Ejection Fraction: Diagnosis and Management

Heart Failure with Reduced Ejection Fraction (HFrEF) is a clinical syndrome characterized by the heart's inability to pump sufficient blood to meet the body's metabolic demands due to impaired systolic function of the left ventricle, typically defined by a left ventricular ejection fraction (LVEF) of 40% or less. Treatment for HFrEF focuses on guideline-directed medical therapy (GDMT) including angiotensin receptor-neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce mortality and morbidity. Diuretics are used for symptom relief from congestion, and device therapies like implantable cardioverter-defibrillators (ICD) or cardiac resynchronization therapy (CRT) may be indicated for selected patients. Lifestyle modifications, such as dietary sodium restriction and fluid management, are also crucial. Patients commonly present with progressive exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and fatigue due to reduced forward flow. Physical signs may include peripheral edema, jugular venous distension, pulmonary rales (crackles), an S3 gallop, and hepatomegaly, indicating fluid congestion.

SMLE Preparation Resources

Master the 2026 SMLE

Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.

Try the QBank & Scaled Mocks